Bryan Oncor reports the
results of a Phase I trial of its targeted radiopharmaceutical
therapy using Re-88 P2045, a radiolabeled synthetic peptide, for the
treatment of advanced lung cancer. The trial was conducted at the
University of Maryland and the University of Iowa and published in
the December issue of the Journal of Thoracic Oncology.
This novel approach to cancer treatment combines a synthetic peptide
molecule, P2045, which targets over expressed somatostatin receptors
(SSTR) on tumors, with a radioactive isotope, Re-188, which has been
shown to destroy cancer cells.
The trial results demonstrate that Re-188 P2045 is well tolerated,
and that targeting SSTRs using this approach is feasible. Martin
Magram, MD, an author of the published paper, comments, "This
targeted, personalized approach to therapy has the potential to treat
a large unmet need in cancer treatment. Somatostatin receptors are
expressed not only in lung cancer, but in several other types of
tumors, as well."
This targeted approach can reduce the risk of toxicity to patients in
two ways. First, it enables screening to determine which patients are
most likely to benefit from the treatment. Second, because the
radiolabeled peptide is bound to the SSTRs on the cancer cells, the
dose is concentrated at the tumor site. While the Re-188 P2045 is
retained at the tumor, it clears quickly from the blood, minimizing
"off-target" systemic exposure.
All of the patients in the trial had advanced lung cancer and entered
the study with progressive disease. Over half of the patients had
stable disease at eight weeks with overall survival of more than 11
months.
"We're very encouraged by the results of the Phase I trial, and are
planning further studies to demonstrate the effectiveness of targeted
RE-P2045 therapy," said Christopher Adams, co-founder of Bryan Oncor.
Source
Bryan Oncor